Rubius Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Rubius Therapeutics has a total shareholder equity of $15.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $23.1M and $7.9M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$14.87m |
| Equity | US$15.13m |
| Total liabilities | US$7.94m |
| Total assets | US$23.07m |
Recent financial health updates
Recent updates
Rubius Therapeutics GAAP EPS of -$0.49 beats by $0.03
Aug 09Rubius: Poor Data, Punishing Environment, Beaten Stock
Jun 19Rubius Looks Attractive Before AACR Data Readout
Mar 21Are Rubius Therapeutics, Inc. (NASDAQ:RUBY) Investors Paying Above The Intrinsic Value?
Oct 28
Our Read On Rubius Therapeutics
Jul 11Rubius Therapeutics EPS beats by $0.02
May 10Have Insiders Been Buying Rubius Therapeutics, Inc. (NASDAQ:RUBY) Shares?
Feb 25Rubius Therapeutics (RUBY) Presents At 39th Annual Healthcare Conference - Slideshow
Jan 14Rubius Therapeutics EPS misses by $0.01
Nov 09Rubius Therapeutics' RTX-321 shows dual mechanism of action in HPV-positive cancers
Oct 28Financial Position Analysis
Short Term Liabilities: RUBY's short term assets ($20.2M) exceed its short term liabilities ($7.9M).
Long Term Liabilities: RUBY has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: RUBY is debt free.
Reducing Debt: RUBY has no debt compared to 5 years ago when its debt to equity ratio was 5.6%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if RUBY has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if RUBY has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.